Asensus Surgical 2021 Annual Meeting of Stockholders Is Adjourned to July 22, 2021
29 Junho 2021 - 1:15PM
Business Wire
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
patient to pioneer a new era of Performance-Guided Surgery™, today
announced that the Company’s 2021 Annual Meeting of Stockholders,
scheduled to be held on Tuesday, June 29, 2021 at 11:00 a.m.
(Eastern Time), was again adjourned to Thursday, July 22, 2021 at
1:00 p.m. (Eastern Time). The Annual Meeting will be held
virtually.
The Company adjourned the Annual Meeting a second time to allow
its retail stockholders additional time to consider and vote on
each of the proposals, which are described in the Proxy
Statement.
Each stockholder’s vote matters and is important no matter how
many shares are owned. The Company requests that its stockholders
please take the time to read and respond to the Company’s proxy
materials that were previously provided to them and vote promptly.
Voting over the phone or on the Internet will require that its
stockholders have their proxy control number available. That number
is either printed on the proxy, if stockholders received a physical
copy of the proxy materials, or Notice of Internet Availability, if
the proxy materials were electronically delivered. Stockholders who
have sold their shares but were a holder of record at the close of
business on April 8, 2021, the record date for the Annual Meeting,
remain entitled to vote. The Board encourages stockholders to
vote “FOR” each of the proposals.
Proxies submitted to date for the Annual Meeting continue to be
valid and will be voted at the Annual Meeting on July 22, 2021 in
accordance with the stockholder’s instructions.
Stockholders who need assistance in submitting their proxy or
voting their shares should call the Company’s proxy solicitor,
Alliance Advisors at 844-858-7383.
About Asensus Surgical, Inc. Asensus Surgical, Inc. is
digitizing the interface between the surgeon and patient to pioneer
a new era of Performance-Guided Surgery by unlocking the clinical
intelligence to enable consistently superior outcomes and a new
standard of surgery. This builds upon the foundation of Digital
Laparoscopy with the Senhance Surgical System powered by the
Intelligent Surgical Unit™ (ISU™) to increase surgeon control and
reduce surgical variability. With the addition of machine vision,
augmented intelligence, and deep learning capabilities throughout
the surgical experience, we intend to holistically address the
current clinical, cognitive and economic shortcomings that drive
surgical outcomes and value-based healthcare. Learn more about
Performance-Guided Surgery and Digital Laparoscopy with the
Senhance Surgical System here: www.senhance.com. Now available for
sale in the US, EU, Japan, Russia, and select other countries. For
a complete list of indications for use, visit:
www.senhance.com/indications. For more information, visit
www.asensus.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210629005900/en/
INVESTOR CONTACT: Mark Klausner or Mike Vallie,
443-213-0499 invest@asensus.com or MEDIA CONTACT: Kristin
Schaeffer CG Life kschaeffer@cglife.com
Asensus Surgical, Inc. (NYSE:ASXC)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Asensus Surgical, Inc. (NYSE:ASXC)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025